Table 4.
Expected total costs, expected total utilities, ICERs and expected net benefit at a £20 000 willingness-to-pay threshold based on abstinence alone.
| Intervention | Total costs | Total QALYs | ICER | ENB | Median rank (IQR) |
|---|---|---|---|---|---|
| Bupropion low | £10 219 | 11.135 | 3159 (3114, 3204) | 11 (9-12) | |
| NRT low | £10 231 | 10.977 | Dominated | 0 | 14 (14-14) |
| NRT high | £10 238 | 11.198 | Extendedly dominated | 4400 (4365, 4434) | 7 (6-8) |
| Bupropion STD | £10 240 | 11.130 | Dominated | 3041 (3008, 3073) | 11 (10-12) |
| E-cigarette high | £10 248 | 11.295 | Extendedly dominated | 6335 (6269, 6401) | 4 (3-6) |
| E-cigarette low | £10 250 | 11.332 | £159 | 7072 (6958, 7187) | 4 (2-8) |
| NRT STD | £10 264 | 11.162 | Dominated | 3657 (3628, 3686) | 9 (8-10) |
| Bupropion std + NRT high | £10 319 | 11.168 | Dominated | 3721 (3647, 3794) | 10 (6-13) |
| Varenicline low | £10 320 | 11.138 | Dominated | 3120 (3076, 3164) | 11 (9-12) |
| Varenicline STD | £10 327 | 11.254 | Dominated | 5434 (5399, 5469) | 5 (4-6) |
| Varenicline STD + NRT high | £10 402 | 11.214 | Dominated | 4556 (4492, 4619) | 10 (6-13) |
| Varenicline STD + bupropion STD | £10 415 | 11.314 | Dominated | 6558 (6475, 6642) | 4 (3-7) |
| Varenicline low + NRT STD | £10 446 | 11.476 | Extendedly dominated | 9759 (9636, 9882) | 2 (1-4) |
| Varenicline STD + NRT STD | £10 447 | 11.483 | £1,302 | 9895 (9799, 9991) | 2 (1-3) |
ENB indicates expected net benefit; ICER, Incremental cost-effectiveness ratios; IQR, interquartile range; NRT, nicotine replacement therapy; QALY, quality adjusted life years; STD, standard.